Convert HbA1c between NGSP (%) and IFCC (mmol/mol), estimate average glucose, assess diabetes risk, and determine glycemic control targets.
Hemoglobin A1c (HbA1c) is the gold standard biomarker for assessing long-term glycemic control and is central to diagnosing and managing diabetes mellitus. It reflects the average blood glucose level over the preceding 2–3 months by measuring the percentage of hemoglobin that has been glycated — bound to glucose molecules during the lifespan of red blood cells.
This calculator performs bidirectional conversion between the NGSP/DCCT percentage format used in the United States and the IFCC mmol/mol standard used internationally. It also estimates average glucose (eAG) using the validated ADAG equation, categorizes results according to American Diabetes Association (ADA) diagnostic thresholds, and calculates individualized A1c targets based on patient age and comorbidities.
Understanding your A1c is critical because every 1% reduction in HbA1c is associated with approximately 21% reduction in diabetes-related deaths, 37% reduction in microvascular complications, and 14% reduction in myocardial infarction according to landmark UKPDS trial data. The calculator also flags conditions known to cause A1c inaccuracy — including hemoglobinopathies, iron deficiency anemia, recent blood transfusion, and chronic kidney disease — helping clinicians choose appropriate alternative tests when needed.
This calculator provides instant dual-unit A1c conversion, estimated average glucose calculation using the validated ADAG equation, and personalized risk stratification. It also checks concordance between fasting glucose and A1c to flag conditions that may affect A1c accuracy, and helps identify individualized A1c targets based on patient age and clinical context.
IFCC = (NGSP - 2.15) × 10.929; eAG (mg/dL) = 28.7 × A1c - 46.7 (ADAG study equation). Microvascular relative risk ≈ 1.37^((A1c - 6) × 2) for A1c ≥ 6.5%.
Result: eAG = 169 mg/dL (9.4 mmol/L), IFCC = 58 mmol/mol, Suboptimal Control, Target <7.0%
An A1c of 7.5% converts to 58 mmol/mol and indicates an estimated average glucose of 169 mg/dL. This is above the ADA target of <7% for most adults, placing the patient in "Suboptimal Control" with elevated microvascular risk.
Use consistent units, verify assumptions, and document conversion standards for repeatable outcomes.
Most mistakes come from mixed standards, rounding too early, or misread labels. Recheck final values before use. ## Practical Notes
Use this for repeatability, keep assumptions explicit. ## Practical Notes
Track units and conversion paths before applying the result. ## Practical Notes
Use this note as a quick practical validation checkpoint. ## Practical Notes
Keep this guidance aligned to expected inputs. ## Practical Notes
Use as a sanity check against edge-case outputs. ## Practical Notes
Capture likely mistakes before publishing this value. ## Practical Notes
Document expected ranges when sharing results.
A normal HbA1c is below 5.7% (39 mmol/mol). Between 5.7% and 6.4% is classified as pre-diabetes. At 6.5% or above on two separate tests, diabetes is diagnosed per ADA guidelines.
HbA1c reflects average glucose over 2-3 months. An A1c of 7% corresponds to approximately 154 mg/dL (8.6 mmol/L) using the validated ADAG equation.
Several conditions cause discordance: iron deficiency falsely raises A1c, hemolytic anemia lowers it, and blood glucose variability (frequent highs and lows averaging out) can mask poor control. Use this as a practical reminder before finalizing the result.
NGSP (National Glycohemoglobin Standardization Program) reports in %, while IFCC (International Federation of Clinical Chemistry) reports in mmol/mol. The US primarily uses NGSP; Europe and much of the world uses IFCC.
HbA1c may be unreliable with hemoglobin variants (HbS, HbC, HbE). Some assays are affected differently. Alternatives include fructosamine, glycated albumin, and continuous glucose monitoring.
The ADA recommends A1c every 3 months for patients not meeting targets or after therapy changes, and every 6 months for those with stable, controlled diabetes. Keep this note short and outcome-focused for reuse.
For otherwise healthy older adults, <7.5% is reasonable. For those with multiple comorbidities or limited life expectancy, <8.0% may be appropriate to avoid hypoglycemia.